Develops drug candidates targeting chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis, for patients with these conditions.
10-K for FY2025, filed Mar 5, 2026
Evommune earns money by licensing drug candidates to partners: partners pay upfront for the rights, may make further payments when development or sales milestones are reached, and may pay a share of product sales. Payments follow schedules set in each agreement.
10-K for FY2025, filed Mar 5, 2026Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s consolidated…View ↗
The terms of the Company’s license agreements typically may include payment to the Company of one or more of the following: non-refundable…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates…View ↗
Royalties: If the Company is entitled to receive sales-based royalties from its licensees, including milestone payments based on the level…View ↗
The Company receives payments from its licensees based on schedules established in each contract. Upfront payments and fees are recorded as…View ↗
$13M
10-K for FY2025, filed Mar 5, 2026
$13M ↗
Evommune grants license rights to partners through agreements; Maruho holds an exclusive license to develop and commercialize EVO756 in Japan.
10-K for FY2025, filed Mar 5, 2026
No. It lost $68.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$30.9MView ↗
8-K, filed Nov 4, 2026
On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Hinova…View ↗
8-K, filed Sep 9, 2026
On September 8, 2026, the Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled…View ↗
Loading...